Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monepantel - PharmAust

Next Previous
Drug Profile

Monepantel - PharmAust

Alternative Names: NUZ-001; PPL-1; S-Monepantel

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pitney Pharmaceuticals
  • Developer Neurizon Therapeutics; PharmAust
  • Class Acetonitriles; Anthelmintics; Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 2 modulators; Cyclin-dependent kinase 4 modulators; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Motor neuron disease
  • Preclinical Amyotrophic lateral sclerosis; Huntington's disease

Most Recent Events

  • 06 Oct 2025 US FDA lifts the clinical hold for monepantel for Amyotrophic lateral sclerosis in USA
  • 06 Oct 2025 Neurizon Therapeutics plans the phase II/III HEALEY ALS trial for Amyotrophic lateral sclerosis in USA (PO), in the fourth quarter of 2025
  • 20 Aug 2025 Efficacy and adverse events data from a phase I trial in Motor neuron disease released by PharmAust

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top